Table 5.
Clinical trials and outcomes after haplo-HSCT with suicide gene therapy.
| Author | Diagnosis/Patient Number | Donor | Conditioning | GvHD Prophylaxis |
Graft Composition | Survival | CI of aGvHD | CI of cGvHD |
|---|---|---|---|---|---|---|---|---|
| Ciceri, F. et al. Lancet Oncol. 2009 [122] | Adult with malignant diseases (n = 50) 22 received TK cells |
haplo | MAC | ATG (n = 45) | CD34+ cells/kg: 11.6 × 106
(range: 4.6 × 106 to 16.8 × 106) CD3+ cells/kg: 1 × 104 (range: 0.26 × 104 to 10 × 104) |
3y OS 49% | Grade I–IV 45% | Extensive cGvHD 4% |
MAC: myeloablative conditioning regimen; ATG: anti-thymocyte globulin; TK: lymphocytes expressing herpes simplex thymidine kinase suicide gene.